The John B. Pierce Laboratory, New Haven, CT, USA.
J Physiol. 2011 Feb 15;589(Pt 4):975-86. doi: 10.1113/jphysiol.2010.194563. Epub 2010 Dec 20.
Women are more susceptible to orthostatic intolerance. Peripheral α-adrenergic responsiveness is important in orthostasis and is lower in women compared to men, and is modulated by female sex hormones. We tested the hypothesis that oestradiol attenuates peripheral cutaneous adrenergic responses in women with low orthostatic tolerance (LT), whereas progesterone enhances adrenergic responses in women with high orthostatic tolerance (HT). After completing a maximal lower body negative pressure test to determine level of orthostatic tolerance (cumulative stress index, CSI), women self administered a gonadotropin releasing hormone (GnRH) antagonist for 16 days to suppress endogenous sex hormone production. Oestradiol (E2, 0.2 mg day−1, patch; days 4–16), and progesterone (P4, 200 mg day−1, oral; days 12–16) were administered. Skin blood flow responses to graded intradermal microdialysis infusions of noradrenaline (NA) were measured during GnRH antagonist, E2, and E2+P4, in eight HT (s.e.m. = 22 ± 1 years, CSI −871 ± 86 mmHg min) and eight LT (21 ± 1 years, CSI −397 ± 65 mmHg min) women. In separate probes, NA was infused alone, and co-infused with the nitric oxide synthase inhibitor NG-monomethyl-l-arginine (l-NMMA, 10 mm), the non-selective cyclooxygenase inhibitor ketorolac tromethamine (Keto, 10 mm), and combined l-NMMA + Keto (10 mm each). Progesterone administration enhanced adrenergic responses in HT women (logEC50 GnRH −4.02 ± 0.39, E2+P4 −5.18 ± 0.31, P < 0.05); this response was reversed with Keto (E2+P4 logEC50 NA+Keto −3.82 ± 0.35, P < 0.05). In contrast, no change in adrenergic responsiveness occurred in LT women during any hormone condition. These data indicate differential regulation of cutaneous adrenergic responses by progesterone via the cyclooxygenase pathway in women with high and low orthostatic tolerance.
女性更容易出现体位不耐受。外周 α-肾上腺素能反应在体位中很重要,且女性的外周 α-肾上腺素能反应低于男性,且受女性性激素调节。我们假设雌激素会减弱体位不耐受(LT)女性的外周皮肤肾上腺素能反应,而孕激素会增强体位耐受力(HT)女性的肾上腺素能反应。在完成最大下体负压测试以确定体位耐受力水平(累积应激指数,CSI)后,女性使用促性腺激素释放激素(GnRH)拮抗剂进行 16 天治疗以抑制内源性性激素的产生。给予雌二醇(E2,0.2 mg 天-1,贴片;第 4-16 天)和孕酮(P4,200 mg 天-1,口服;第 12-16 天)。在 GnRH 拮抗剂、E2 和 E2+P4 期间,测量了 8 名 HT(均数±标准差=22±1 岁,CSI-871±86mmHg min)和 8 名 LT(21±1 岁,CSI-397±65mmHg min)女性接受分级皮内微透析输注去甲肾上腺素(NA)时的皮肤血流反应。在单独的探针中,单独输注 NA,并与一氧化氮合酶抑制剂 NG-单甲基-L-精氨酸(l-NMMA,10mm)、非选择性环氧化酶抑制剂酮咯酸氨丁三醇(Keto,10mm)和联合 l-NMMA+Keto(各 10mm)共同输注。孕激素给药增强了 HT 女性的肾上腺素能反应(logEC50 GnRH-4.02±0.39,E2+P4-5.18±0.31,P<0.05);用 Keto 逆转了这一反应(E2+P4 logEC50 NA+Keto-3.82±0.35,P<0.05)。相比之下,在任何激素条件下,LT 女性的肾上腺素能反应均无变化。这些数据表明,孕酮通过环氧化酶途径对高低体位耐受力女性的皮肤肾上腺素能反应进行差异调节。